We successfully constructed a “bioactive compound (genistein, hesperetin, lanceolarin, and trifolirhizin)-target (p53 and CHEK1)-cell cycle pathway” network for the anti-CRC effect of CKI. The gene discussed is CHKA; the disease is colorectal carcinoma.